Biomarker · Gene alteration

BRCA1 mutation

Pathogenic germline or somatic BRCA1 variants detected by sequencing of blood or tumor; used as a predictive marker for PARP inhibitors and as a hereditary cancer-risk marker.

CI-BIO-00000032BRCA1 graph →NCIt C19635

Also calledBRCA1-mutated · gBRCA1 · germline BRCA1 · somatic BRCA1

Derived

Associated cancers (16)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Ovarian Neoplasm	13	12	1	—	4 / 8 / 1 / 0 / 0
Malignant Pancreatic Neoplasm	4	4	—	—	0 / 4 / 0 / 0 / 0
Ovarian Carcinoma	4	3	1	—	1 / 3 / 0 / 0 / 0
Malignant Prostate Neoplasm	3	2	1	—	0 / 2 / 1 / 0 / 0
Triple-Negative Breast Carcinoma

Derived

Drugs with predictive evidence (15)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
OlaparibSmall Molecule	22	21	1	A	21 / 1	Breast Carcinoma, Castration-Resistant Prostate Carcinoma, Lung Carcinoma, Malignant Biliary Tract Neoplasm +9
RucaparibSmall Molecule	7	7

Curated evidence

Predictive evidence items (41)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–41 of 41 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRCA1 Mutation + BRCA2 MutationBRCA2 BRCA1

Regulatory

Approvals mentioning the linked drugs (179)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

BRCA1 Mutation19
Olaparib	Castration-Resistant Prostate Carcinoma	Predictive	A	Supports Sensitivity Response	4	accepted	EID11203 This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID1370 In this phase 1 trial, 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only … (full text at CIViC) PMID 19553641 · Fong et al., 2009 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	5	accepted	EID7274 In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	1	accepted	EID7275 In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID1772 In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC) PMID 21862407 · Gelmon et al., 2011 · Open in CIViC	civic
Cediranib + OlaparibCombination	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID1677 46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC) PMID 25218906 · Liu et al., 2014 · Open in CIViC	civic
Rucaparib	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	5	accepted	EID11136 Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	5	accepted	EID11138 Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID1897 A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID6341 A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic
Cisplatin + OxaliplatinSubstitutes	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID5915 Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC) PMID 25072261 · Golan et al., 2014 · Open in CIViC	civic
Olaparib	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5914 Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Five (21.7%) patients had a BRCA1 mutation. All but one had received prior gemcitabine, and 65% had … (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC	civic
Veliparib	Malignant Pancreatic Neoplasm	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID5934 Veliparib 400mg BID was administered to patients with germline BRCA1/2-mutated pancreatic cancer. Sixteen patients were enrolled. All except two (12.5%) had previously been treated with platinum thera… (full text at CIViC) PMID 29223478 · Lowery et al., 2018 · Open in CIViC	civic
Cisplatin + Gemcitabine + VeliparibCombination	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5932 In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC) PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC	civic
Platinum Compound	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1529 In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
〃	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1531 In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1684 In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC) PMID 25847936 · Isakoff et al., 2015 · Open in CIViC	civic
Olaparib	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID1775 In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib. PMID 21862407 · Gelmon et al., 2011 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	4	accepted	EID5830 Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC) PMID 28792849 · 2017 · Open in CIViC	civic

BRCA1 Loss-of-function9
Pidnarulex + QuarfloxinSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	4	accepted	EID1924 The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenog… (full text at CIViC) PMID 28211448 · Xu et al., 2017 · Open in CIViC	civic
Talazoparib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID4838 In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC	civic
Olaparib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID211 The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC	civic
Talazoparib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID4876 In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC	civic
Olaparib	Malignant Prostate Neoplasm	Predictive	C	Supports Sensitivity Response	2	accepted	EID845 1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study. PMID 26510020 · Mateo et al., 2015 · Open in CIViC	civic
〃	Pancreatic Adenocarcinoma	Predictive	A	Supports Sensitivity Response	5	accepted	EID7384 In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC) PMID 31157963 · Golan et al., 2019 · Open in CIViC	civic
〃	Triple-Negative Breast CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID11216 Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	A	Supports Sensitivity Response	5	accepted	EID11201 Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	5	accepted	EID5815 302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had signi… (full text at CIViC) PMID 28578601 · Robson et al., 2017 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02320371) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 11, 2015	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION (DIN 02366053) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 28, 2020	Jun 10, 2013	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02126680) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 30, 1997	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION (DIN 02125439) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1994	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION LIQ 10MG/ML (DIN 01990438) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1992	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as PARAPLATIN-AQ INJ 10MG/ML (DIN 00788759) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 30, 2007	Dec 31, 1989	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as PARAPLATIN INJ 150MG/VIAL (DIN 00680060) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 9, 1996	Dec 31, 1986	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION (DIN 02535289) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02570963) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION (DIN 02528916) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Carboplatin	CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION, BP (DIN 02420228) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Carboplatin	US FDA	Ovarian Carcinoma	As a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy.	approved	Aug 8, 2025	openfda
Carboplatin	US FDA	Ovarian Carcinoma	As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma.	approved	Aug 8, 2025	openfda
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02536285) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 23, 2024	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02403188) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 29, 2013	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION, MYLAN STD. (DIN 02396890) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 6, 2016	Jun 12, 2013	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION, BP (DIN 02355183) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 10, 2012	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02366711) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 25, 2022	Sep 29, 2011	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02126613) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 9, 1997	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as PLATINOL AQ INJ 1MG/ML (DIN 00788740) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 30, 2001	Dec 31, 1988	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJ 1MG/ML (DIN 00692743) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1986	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJ 0.5MG/ML (DIN 00644293) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 10, 1996	Dec 31, 1985	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as PMS-CISPLATIN (DIN 02409194) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02409186) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02393832) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02422034) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cisplatin	US FDA	—	Efficacy supplement 1993-04-22 (see label)	approved	Apr 22, 1993	openfda
Cisplatin	US FDA	—	Efficacy supplement 1981-12-29 (see label)	approved	Dec 29, 1981	openfda
Cisplatin	US FDA	Malignant Bladder Neoplasm	INDICATIONS Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.	approved	Dec 19, 1978	openfda
Gemcitabine	CA Health Canada	—	Marketed in Canada as ACT GEMCITABINE (DIN 02433117) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 2019	May 2, 2016	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02407310) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 8, 2017	Jun 26, 2014	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02407302) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 8, 2017	Jun 26, 2014	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION CONCENTRATE (DIN 02423510) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 7, 2017	Apr 17, 2014	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE INJECTION (DIN 02412292) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 24, 2013	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE SUN FOR INJECTION (DIN 02373173) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Dec 19, 2024	Mar 21, 2013	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE SUN FOR INJECTION (DIN 02373181) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Dec 19, 2024	Mar 21, 2013	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE INJECTION (DIN 02402831) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 20, 2013	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02370034) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 28, 2025	Aug 31, 2011	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02324202) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 17, 2020	Aug 31, 2011	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02318741) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2018	Oct 1, 2009	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02324210) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 28, 2025	Jul 16, 2009	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02305526) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Sep 10, 2008	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02305534) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Jun 27, 2008	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02298775) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2018	Jan 25, 2008	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02298783) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2014	Dec 27, 2007	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE HYDROCHLORIDE FOR INJECTION (DIN 02302098) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2019	Nov 20, 2007	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE HYDROCHLORIDE FOR INJECTION (DIN 02302101) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2019	Nov 20, 2007	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMZAR (200MG/VIAL) (DIN 02230308) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Mar 11, 2015	Mar 10, 1997	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMZAR (1GM/VIAL) (DIN 02230309) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Nov 1, 2015	Mar 10, 1997	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION USP (DIN 02409933) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd

Associated cancers (16)

Drugs with predictive evidence (15)

Predictive evidence items (41)

Approvals mentioning the linked drugs (179)

Active trials (499)

Linked publications (34)